Disabled-2: A modular scaffold protein with multifaceted functions in signaling

BioEssays

Volumn 38, Issue , 2016, Pages S45-S55

  Finkielstein, Carla V ^a   Capelluto, Daniel G S ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

adaptor protein; Disabled 2; endocytosis; phosphatidylinositol 4,5 bisphosphate; platelets; sulfatides; tumor suppressor

Indexed keywords

ADAPTOR PROTEIN; CELL SURFACE RECEPTOR; CLATHRIN; DISABLED 2 PROTEIN; INTEGRIN; INTEGRIN RECEPTOR; LIPID; PHOSPHATIDYLINOSITIDE; SCAFFOLD PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CELL INTERACTION; CELL MATURATION; CELL SURFACE; CYTOSOL; ENDOCYTOSIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSIOLOGICAL PROCESS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

EID: 84978829800     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201670907     Document Type: Review

References (135)

1. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, et al. 1994. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 52: 247–52.
2. Huang Y, Friess H, Kleeff J, Esposito I, et al. 2001. Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis. Lab Invest 81: 863–73.
3. Kleeff J, Huang Y, Mok SC, Zimmermann A, et al. 2002. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis Colon Rectum 45: 1242–8.
4. Anupam K, Tusharkant C, Gupta SD, Ranju R. 2006. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol 12: 6041–5.
5. Morris SM, Cooper JA. 2001. Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic 2: 111–23.
6. Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, et al. 2002. Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. Traffic 3: 331–41.
7. Zhou J, Hsieh JT. 2001. The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 276: 27793–8.
8. Rosenbauer F, Kallies A, Scheller M, Knobeloch KP, et al. 2002. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J 21: 211–20.
9. Tseng CP, Huang CH, Tseng CC, Lin MH, et al. 2001. Induction of disabled-2 gene during megakaryocyte differentiation of k562 cells. Biochem Biophys Res Commun 285: 129–35.
10. Huang CL, Cheng JC, Stern A, Hsieh JT, et al. 2006. Disabled-2 is a novel alphaIIb-integrin-binding protein that negatively regulates platelet-fibrinogen interactions and platelet aggregation. J Cell Sci 119: 4420–30.
11. Huang CH, Cheng JC, Chen JC, Tseng CP. 2007. Evaluation of the role of Disabled-2 in nerve growth factor-mediated neurite outgrowth and cellular signalling. Cell Signal 19: 1339–47.
12. Vazquez-Carretero MD, Garcia-Miranda P, Calonge ML, Peral MJ, et al. 2011. Regulation of Dab2 expression in intestinal and renal epithelia by development. J Cell Biochem 112: 354–61.
13. Fazili Z, Sun W, Mittelstaedt S, Cohen C, et al. 1999. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 18: 3104–13.
14. Tao W, Moore R, Smith ER, Xu XX. 2014. Hormonal induction and roles of Disabled-2 in lactation and involution. PLoS One 9: e110737.
15. Xu XX, Yang W, Jackowski S, Rock CO. 1995. Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem 270: 14184–91.
16. Maurer ME, Cooper JA. 2005. Endocytosis of megalin by visceral endoderm cells requires the Dab2 adaptor protein. J Cell Sci 118: 5345–55.
17. Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, et al. 2002. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J 21: 4915–26.
18. Gertler FB, Bennett RL, Clark MJ, Hoffmann FM. 1989. Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell 58: 103–13.
19. Howell BW, Gertler FB, Cooper JA. 1997. Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J 16: 121–32.
20. Zhou J, Scholes J, Hsieh JT. 2003. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem 278: 6936–41.
21. Karam JA, Shariat SF, Huang HY, Pong RC, et al. 2007. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13: 4400–6.
22. Mok SC, Chan WY, Wong KK, Cheung KK, et al. 1998. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16: 2381–7.
23. Yang DH, Smith ER, Cohen C, Wu H, et al. 2002. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 94: 2380–92.
24. Yang DH, Smith ER, Roland IH, Sheng Z, et al. 2002. Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. Dev Biol 251: 27–44.
25. Yang DH, Fazili Z, Smith ER, Cai KQ, et al. 2006. Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. Am J Pathol 169: 258–67.
26. Yang DH, Cai KQ, Roland IH, Smith ER, et al. 2007. Disabled-2 is an epithelial surface positioning gene. J Biol Chem 282: 13114–22.
27. He J, Smith ER, Xu XX. 2001. Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. J Biol Chem 276: 26814–8.
28. Whitmarsh AJ. 2007. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim Biophys Acta 1773: 1285–98.
29. Yang DH, Smith ER, Cai KQ, Xu XX. 2009. C-Fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development. Dev Dyn 238: 514–23.
30. Tseng CP, Ely BD, Li Y, Pong RC, et al. 1998. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 139: 3542–53.
31. Bagadi SA, Prasad CP, Srivastava A, Prashad R, et al. 2007. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Treat 104: 277–86.
32. Hannigan A, Smith P, Kalna G, Lo Nigro C, et al. 2010. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 120: 2842–57.
33. Tong JH, Ng DC, Chau SL, So KK, et al. 2010. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 10: 253.
34. Yang Y, Zhang Q, Xu F, Chang C, et al. 2012. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome. Eur J Haematol 89: 469–77.
35. Xie XM, Zhang ZY, Yang LH, Yang DL, et al. 2013. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Int J Oncol 43: 1636–42.
36. Li C, Chen J, Chen T, Xu Z, et al. 2015. Aberrant hypermethylation at sites -86 to 226 of DAB2 gene in non-small cell lung cancer. Am J Med Sci 349: 425–31.
37. Iorio MV, Ferracin M, Liu CG, Veronese A, et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–70.
38. Chao A, Lin CY, Lee YS, Tsai CL, et al. 2012. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 31: 764–75.
39. Yan ZX, Wu LL, Xue K, Zhang QL, et al. 2014. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 28: 880–7.
40. Traub LM, Bonifacino JS. 2013. Cargo recognition in clathrin-mediated endocytosis. Cold Spring Harb Perspect Biol 5: a016790.
41. Maldonado-Baez L, Wendland B. 2006. Endocytic adaptors: recruiters, coordinators and regulators. Trends Cell Biol 16: 505–13.
42. Morris SM, Tallquist MD, Rock CO, Cooper JA. 2002. Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J 21: 1555–64.
43. Kawasaki F, Iyer J, Posey LL, Sun CE, et al. 2011. The DISABLED protein functions in CLATHRIN-mediated synaptic vesicle endocytosis and exoendocytic coupling at the active zone. Proc Natl Acad Sci U S A 108: E222–9.
44. Stolt PC, Vardar D, Blacklow SC. 2004. The dual-function disabled-1 PTB domain exhibits site independence in binding phosphoinositide and peptide ligands. Biochemistry 43: 10979–87.
45. Chao WT, Kunz J. 2009. Focal adhesion disassembly requires clathrin-dependent endocytosis of integrins. FEBS Lett 583: 1337–43.
46. Oleinikov AV, Zhao J, Makker SP. 2000. Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin. Biochem J 347: 613–21.
47. Lee J, Retamal C, Cuitino L, Caruano-Yzermans A, et al. 2008. Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes. J Biol Chem 283: 11501–8.
48. Maurer ME, Cooper JA. 2006. The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH. J Cell Sci 119: 4235–46.
49. Cuitino L, Matute R, Retamal C, Bu G, et al. 2005. ApoER2 is endocytosed by a clathrin-mediated process involving the adaptor protein Dab2 independent of its Rafts' association. Traffic 6: 820–38.
50. Li Y, Marzolo MP, van Kerkhof P, Strous GJ, et al. 2000. The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. J Biol Chem 275: 17187–94.
51. Yun M, Keshvara L, Park CG, Zhang YM, et al. 2003. Crystal structures of the Dab homology domains of mouse disabled 1 and 2. J Biol Chem 278: 36572–81.
52. Stolt PC, Jeon H, Song HK, Herz J, et al. 2003. Origins of peptide selectivity and phosphoinositide binding revealed by structures of disabled-1 PTB domain complexes. Structure 11: 569–79.
53. Howell BW, Lanier LM, Frank R, Gertler FB, et al. 1999. The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Mol Cell Biol 19: 5179–88.
54. Dvir H, Shah M, Girardi E, Guo L, et al. 2012. Atomic structure of the autosomal recessive hypercholesterolemia phosphotyrosine-binding domain in complex with the LDL-receptor tail. Proc Natl Acad Sci U S A 109: 6916–21.
55. Conner SD, Schmid SL. 2003. Regulated portals of entry into the cell. Nature 422: 37–44.
56. Balla T. 2013. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev 93: 1019–137.
57. Nakayama M, Nakayama A, van Lessen M, Yamamoto H, et al. 2013. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol 15: 249–60.
58. Tseng CP, Ely BD, Pong RC, Wang Z, et al. 1999. The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem 274: 31981–6.
59. He J, Xu J, Xu XX, Hall RA. 2003. Cell cycle-dependent phosphorylation of Disabled-2 by cdc2. Oncogene 22: 4524–30.
60. Chetrit D, Barzilay L, Horn G, Bielik T, et al. 2011. Negative regulation of the endocytic adaptor disabled-2 (Dab2) in mitosis. J Biol Chem 286: 5392–403.
61. Gao Z, Godbout R. 2013. Reelin-Disabled-1 signaling in neuronal migration: splicing takes the stage. Cell Mol Life Sci 70: 2319–29.
62. Bond LM, Arden SD, Kendrick-Jones J, Buss F, et al. 2012. Dynamic exchange of myosin VI on endocytic structures. J Biol Chem 287: 38637–46.
63. Bonifacino JS, Traub LM. 2003. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 72: 395–447.
64. Teckchandani A, Mulkearns EE, Randolph TW, Toida N, et al. 2012. The clathrin adaptor Dab2 recruits EH domain scaffold proteins to regulate integrin beta1 endocytosis. Mol Biol Cell 23: 2905–16.
65. Traub LM. 2009. Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat Rev Mol Cell Biol 10: 583–96.
66. Inoue A, Sato O, Homma K, Ikebe M. 2002. DOC-2/DAB2 is the binding partner of myosin VI. Biochem Biophys Res Commun 292: 300–7.
67. Spudich G, Chibalina MV, Au JS, Arden SD, et al. 2007. Myosin VI targeting to clathrin-coated structures and dimerization is mediated by binding to Disabled-2 and PtdIns(4,5)P2. Nat Cell Biol 9: 176–83.
68. Wells AL, Lin AW, Chen LQ, Safer D, et al. 1999. Myosin VI is an actin-based motor that moves backwards. Nature 401: 505–8.
69. Buss F, Arden SD, Lindsay M, Luzio JP, et al. 2001. Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-mediated endocytosis. EMBO J 20: 3676–84.
70. Yu C, Feng W, Wei Z, Miyanoiri Y, et al. 2009. Myosin VI undergoes cargo-mediated dimerization. Cell 138: 537–48.
71. Aschenbrenner L, Lee T, Hasson T. 2003. Myo6 facilitates the translocation of endocytic vesicles from cell peripheries. Mol Biol Cell 14: 2728–43.
72. Hasson T. 2003. Myosin VI: two distinct roles in endocytosis. J Cell Sci 116: 3453–61.
73. Penheiter SG, Singh RD, Repellin CE, Wilkes MC, et al. 2010. Type II transforming growth factor-beta receptor recycling is dependent upon the clathrin adaptor protein Dab2. Mol Biol Cell 21: 4009–19.
74. Chibalina MV, Seaman MN, Miller CC, Kendrick-Jones J, et al. 2007. Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment. J Cell Sci 120: 4278–88.
75. Collaco A, Jakab R, Hegan P, Mooseker M, et al. 2010. Alpha-AP-2 directs myosin VI-dependent endocytosis of cystic fibrosis transmembrane conductance regulator chloride channels in the intestine. J Biol Chem 285: 17177–87.
76. Cihil KM, Ellinger P, Fellows A, Stolz DB, et al. 2012. Disabled-2 protein facilitates assembly polypeptide-2-independent recruitment of cystic fibrosis transmembrane conductance regulator to endocytic vesicles in polarized human airway epithelial cells. J Biol Chem 287: 15087–99.
77. Hocevar BA, Prunier C, Howe PH. 2005. Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem 280: 25920–7.
78. Prunier C, Howe PH. 2005. Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem 280: 17540–8.
79. Hocevar BA, Smine A, Xu XX, Howe PH. 2001. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 20: 2789–801.
80. Itoh S, Thorikay M, Kowanetz M, Moustakas A, et al. 2003. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem 278: 3751–61.
81. Chaudhury A, Hussey GS, Ray PS, Jin G, et al. 2010. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 12: 286–93.
82. Shapira KE, Hirschhorn T, Barzilay L, Smorodinsky NI, et al. 2014. Dab2 inhibits the cholesterol-dependent activation of JNK by TGF-beta. Mol Biol Cell 25: 1620–8.
83. Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131–42.
84. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, et al. 2001. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 276: 46707–13.
85. Martin JC, Herbert BS, Hocevar BA. 2010. Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br J Cancer 103: 1716–23.
86. Hocevar BA, Mou F, Rennolds JL, Morris SM, et al. 2003. Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J 22: 3084–94.
87. Tauriello DV, Jordens I, Kirchner K, Slootstra JW, et al. 2012. Wnt/beta-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled. Proc Natl Acad Sci U S A 109: E812–20.
88. Simons M, Gault WJ, Gotthardt D, Rohatgi R, et al. 2009. Electrochemical cues regulate assembly of the Frizzled/Dishevelled complex at the plasma membrane during planar epithelial polarization. Nat Cell Biol 11: 286–94.
89. Capelluto DG, Zhao X, Lucas A, Lemkul JA, et al. 2014. Biophysical and molecular-dynamics studies of phosphatidic acid binding by the Dvl-2 DEP domain. Biophys J 106: 1101–11.
90. MacDonald BT, Tamai K, He X. 2009. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9–26.
91. Cliffe A, Hamada F, Bienz M. 2003. A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol 13: 960–6.
92. Jiang Y, Prunier C, Howe PH. 2008. The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin. Oncogene 27: 1865–75.
93. Jiang Y, He X, Howe PH. 2012. Disabled-2 (Dab2) inhibits Wnt/beta-catenin signalling by binding LRP6 and promoting its internalization through clathrin. EMBO J 31: 2336–49.
94. Jackson SP. 2007. The growing complexity of platelet aggregation. Blood 109: 5087–95.
95. Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. 2009. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 94: 700–11.
96. Ma YQ, Qin J, Plow EF. 2007. Platelet integrin alpha(IIb)beta(3): activation mechanisms. J Thromb Haemost 5: 1345–52.
97. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, et al. 1985. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A 82: 8057–61.
98. Drahos KE, Welsh JD, Finkielstein CV, Capelluto DG. 2009. Sulfatides partition disabled-2 in response to platelet activation. PLoS One 4:e8007.
99. Handagama PJ, Shuman MA, Bainton DF. 1989. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 84: 73–82.
100. Harrison P, Wilbourn B, Debili N, Vainchenker W, et al. 1989. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 84: 1320–4.
101. Handagama P, Scarborough RM, Shuman MA, Bainton DF. 1993. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood 82: 135–8.
102. Baurand A, Eckly A, Hechler B, Kauffenstein G, et al. 2005. Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67: 721–33.
103. George JN. 1978. Platelet behavior and aging in the circulation. Prog Clin Biol Res 28: 39–64.
104. Huang CL, Cheng JC, Liao CH, Stern A, et al. 2004. Disabled-2 is a negative regulator of integrin alpha(IIb)beta(3)-mediated fibrinogen adhesion and cell signaling. J Biol Chem 279: 42279–89.
105. Heijnen HF, Debili N, Vainchencker W, Breton-Gorius J, et al. 1998. Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood 91: 2313–25.
106. Hung WS, Huang CL, Fan JT, Huang DY, et al. 2012. The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen. Biochim Biophys Acta 1823: 1778–88.
107. Calderwood DA, Fujioka Y, de Pereda JM, Garcia-Alvarez B, et al. 2003. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A 100: 2272–7.
108. Hartwig JH, Bokoch GM, Carpenter CL, Janmey PA, et al. 1995. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell 82: 643–53.
109. Heraud JM, Racaud-Sultan C, Gironcel D, Albiges-Rizo C, et al. 1998. Lipid products of phosphoinositide 3-kinase and phosphatidylinositol 4',5'-bisphosphate are both required for ADP-dependent platelet spreading. J Biol Chem 273: 17817–23.
110. Racaud-Sultan C, Mauco G, Guinebault C, Plantavid M, et al. 1993. Rapid and transient thrombin stimulation of phosphatidylinositol 4,5-bisphosphate synthesis but not of phosphatidylinositol 3,4-bisphosphate independent of phospholipase C activation in platelets. FEBS Lett 330: 347–51.
111. Rozenvayn N, Flaumenhaft R. 2001. Phosphatidylinositol 4,5-bisphosphate mediates Ca2 + -induced platelet alpha-granule secretion: evidence for type II phosphatidylinositol 5-phosphate 4-kinase function. J Biol Chem 276: 22410–9.
112. Pennings MT, Derksen RH, van Lummel M, Adelmeijer J, et al. 2007. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 5: 369–77.
113. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. 2008. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 6: 1405–12.
114. Keshvara L, Benhayon D, Magdaleno S, Curran T. 2001. Identification of reelin-induced sites of tyrosyl phosphorylation on disabled 1. J Biol Chem 276: 16008–14.
115. Tsai HJ, Huang CL, Chang YW, Huang DY, et al. 2014. Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice. Arterioscler Thromb Vasc Biol 34: 2404–12.
116. Welsh JD, Charonko JJ, Salmanzadeh A, Drahos KE, et al. 2011. Disabled-2 modulates homotypic and heterotypic platelet interactions by binding to sulfatides. Br J Haematol 154: 122–33.
117. Farrah T, Deutsch EW, Omenn GS, Campbell DS, et al. 2011. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10: M110.006353.
118. Teckchandani A, Toida N, Goodchild J, Henderson C, et al. 2009. Quantitative proteomics identifies a Dab2/integrin module regulating cell migration. J Cell Biol 186: 99–111.
119. Cho SY, Jeon JW, Lee SH, Park SS. 2000. p67 isoform of mouse disabled 2 protein acts as a transcriptional activator during the differentiation of F9 cells. Biochem J 352: 645–50.
120. Xiao S, Finkielstein CV, Capelluto DG. 2013. The enigmatic role of sulfatides: new insights into cellular functions and mechanisms of protein recognition. Adv Exp Med Biol 991: 27–40.
121. Chetrit D, Ziv N, Ehrlich M. 2009. Dab2 regulates clathrin assembly and cell spreading. Biochem J 418: 701–15.
122. Ishizuka I. 1997. Chemistry and functional distribution of sulfoglycolipids. Prog Lipid Res 36: 245–319.
123. Alajlouni R, Drahos KE, Finkielstein CV, Capelluto DG. 2011. Lipid-mediated membrane binding properties of Disabled-2. Biochim Biophys Acta 1808: 2734–44.
124. Xiao S, Charonko JJ, Fu X, Salmanzadeh A, et al. 2012. Structure, sulfatide binding properties, and inhibition of platelet aggregation by a Disabled-2 protein-derived peptide. J Biol Chem 287: 37691–702.
125. Xiao S, Zhao X, Finkielstein CV, Capelluto DG. 2014. A rapid procedure to isolate isotopically labeled peptides for NMR studies: application to the Disabled-2 sulfatide-binding motif. J Pept Sci 20: 216–22.
126. Reymond N, d'Agua BB, Ridley AJ. 2013. Crossing the endothelial barrier during metastasis. Nat Rev Cancer 13: 858–70.
127. Merten M, Thiagarajan P. 2001. Role for sulfatides in platelet aggregation. Circulation 104: 2955–60.
128. Coupland LA, Chong BH, Parish CR. 2012. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 72: 4662–71.
129. Dong C, Slattery MJ, Liang S, Peng HH. 2005. Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. Mol Cell Biomech 2: 145–59.
130. Steinman RM. 2012. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30: 1–22.
131. Palucka K, Banchereau J. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: 38–48.
132. Ahmed MS, Byeon SE, Jeong Y, Miah MA, et al. 2015. Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy. Oncoimmunology 4: e984550.
133. Jain N, Nguyen H, Friedline RH, Malhotra N, et al. 2009. Cutting edge: Dab2 is a FOXP3 target gene required for regulatory T cell function. J Immunol 183: 4192–6.
134. Jokubaitis VG, Gresle MM, Kemper DA, Doherty W, et al. 2013. Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 1: 32.
135. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, et al. 1993. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 151: 2132–41.